New cdc guideline for pid treatment
Reading File
Searching the Web
CDC 2025 2026 guidelines pelvic inflammatory disease PID treatment
Finding Sources
Reading Web Page
PID pelvic inflammatory disease treatment regimen antibiotics 2021
Searching PubMed
"pelvic inflammatory disease" treatment guidelines
Here are the CDC 2021 STI Treatment Guidelines for PID (the current CDC standard, published 2021 and still active as of 2026):
CDC Guidelines: Pelvic Inflammatory Disease (PID) Treatment
Diagnosis Threshold
Treat empirically for PID in sexually active women with uterine tenderness, adnexal tenderness, or cervical motion tenderness — no specific etiology required before initiating antibiotics.
Outpatient (IM/Oral) Regimens
For mild-to-moderate PID — outcomes are equivalent to IV therapy in this population.
Recommended Regimen (Preferred)
| Drug | Dose |
|---|---|
| Ceftriaxone | 500 mg IM × 1 dose† |
| + Doxycycline | 100 mg PO BID × 14 days |
| + Metronidazole | 500 mg PO BID × 14 days |
†For persons >150 kg (~300 lbs) with documented gonococcal infection, use 1 g ceftriaxone.
Alternative Outpatient Regimens
- Cefoxitin 2 g IM × 1 dose + Probenecid 1 g PO × 1 dose, PLUS doxycycline 100 mg PO BID × 14 days ± metronidazole 500 mg PO BID × 14 days
- Other parenteral 3rd-gen cephalosporin (e.g., ceftizoxime, cefotaxime) PLUS doxycycline ± metronidazole (same dosing as above)
⚠️ Quinolone-based regimens (levofloxacin, moxifloxacin) are NOT recommended as first-line due to quinolone-resistant N. gonorrhoeae. They may be used only if cephalosporin allergy + low community GC prevalence + reliable follow-up.
Inpatient (Parenteral) Regimens
Indicated for: severe illness, TOA, pregnancy, failure/intolerance of oral therapy, surgical emergency cannot be excluded.
Recommended Parenteral Regimen (Preferred)
| Drug | Dose |
|---|---|
| Ceftriaxone | 1 g IV q24h |
| + Doxycycline | 100 mg IV or PO q12h |
| + Metronidazole | 500 mg IV or PO q12h |
Alternative Parenteral Regimens
| Regimen | Dosing |
|---|---|
| Cefotetan 2 g IV q12h + Doxycycline 100 mg IV/PO q12h | — |
| Cefoxitin 2 g IV q6h + Doxycycline 100 mg IV/PO q12h | — |
| Ampicillin-sulbactam 3 g IV q6h + Doxycycline 100 mg IV/PO q12h | — |
| Clindamycin 900 mg IV q8h + Gentamicin loading 2 mg/kg IV/IM → 1.5 mg/kg q8h (or 3–5 mg/kg/day once daily) | — |
Transition from parenteral to oral: Usually within 24–48 hours of clinical improvement; complete a 14-day total course.
For the clindamycin/gentamicin regimen after transition: use clindamycin 450 mg PO QID or doxycycline 100 mg PO BID. If TOA is present, use clindamycin or metronidazole (not doxycycline alone) for better anaerobic coverage.
Key Management Points
| Consideration | Recommendation |
|---|---|
| Total treatment duration | 14 days for all regimens |
| Reassessment | 72 hours after initiating outpatient treatment |
| Hospitalization for TOA | >24 hours inpatient observation recommended |
| Partner treatment | Treat all partners within past 60 days empirically |
| IUD | No need to remove IUD routinely; removal may be considered if no improvement at 72h |
| Pregnancy | Hospitalize; use parenteral regimen |
Notable Change from Previous Guidelines (2015 → 2021)
The ceftriaxone outpatient dose was increased from 250 mg to 500 mg IM (reflecting the higher dose now recommended for gonorrhea treatment generally). Quinolones were formally removed as a standard option.
The CDC STI guidelines are available at cdc.gov/std/treatment-guidelines/pid.htm.
This is a shared conversation. Sign in to Orris to start your own chat.